Tumour invasion and matrix metalloproteinases

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 3, 2004, Pages 179-186

  Polette, Myriam ^a,c   Nawrocki Raby, Béatrice ^a   Gilles, Christine ^b   Clavel, Christine ^a   Birembaut, Philippe ^a  

^a REIMS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c INSERM   (France)

Author keywords

Matrix metalloproteinases; Tumour invasion

Indexed keywords

CELL ADHESION MOLECULE; GROWTH FACTOR; MATRIX METALLOPROTEINASE;

ANGIOGENESIS; CANCER INVASION; EPITHELIUM; EXTRACELLULAR MATRIX; HOST CELL; HUMAN; MACROMOLECULE; MESENCHYME CELL; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; STROMA CELL;

EID: 1342321843     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.10.008     Document Type: Review

References (74)

1. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
2. Shapiro S.D. Matrix metalloproteinases degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 10:1998;602-608.
3. Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem. 274:1999;21491-21494.
4. Johansson N., Airola K., Grenman R.et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am. J. Pathol. 151:1997;499-508.
5. Nielsen B.S., Rank F., Lopez J.M.et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ to invasive lesion ductal carcinoma. Cancer Res. 61:2001;7091-7100.
6. Hernandez-Barrantes S., Bernardo M., Toth M., Fridman R. Regulation of membrane-type matrix metalloproteinases. Sem. Cancer Biol. 12:2002;131-138.
7. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 14:2000;2123-2133.
8. Mignatti P., Rifkin D.B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein. 49:1996;117-137.
9. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. Hoppe Seyler. 378:1997;151-160.
10. Knauper V., Will H., Lopez-Otin C.et al. Cellular mechanisms for human procollagenase (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271:1996;17124-17131.
11. Kolkenbrock H., Orgel D., Hecker-Kia A., Zimmermann J., Ulrich N. Generation and activity of ternary gelatinase B/TIMP-1/LMW-stromelysin 1 complex. Biol. Chem. Hoppe Seyler. 376:1995;495-500.
12. Liu Y.E., Wang M., Greene J.et al. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase-4 (TIMP-4). J. Biol. Chem. 272:1997;20479-20483.
13. Barsky S.H., Togo S., Garbisa S., Liotta L.A. Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet. 19:1993;296-297.
14. Basset P., Bellocq J.P., Wolf C.et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348:1990;699-704.
15. Nabeshima K., Inoue T., Shimao Y., Sameshima Y. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Annual. 52:2002;255-264.
16. Uria J.A., Stahle-Backdahl M., Seiki M., Fueyo A., Lopez-Otin C. Regulation of collagenase-3 in human breast carcinomas is mediated by stroma-epithelial cell interactions. Cancer Res. 57:1997;4882-4888.
17. Polette M., Gilbert N., Stas I.et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Arch. 424:1994;641-645.
18. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149:1996;273-282.
19. Okada A., Bellocq J.P., Rouyer N.et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2730-2734.
20. Nawrocki B., Polette M., Marchand V.et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulomonarty carcinomas: quantificative and morphological aspects. Int. J. Cancer. 72:1997;556-564.
21. Bisson C., Blacher S., Polette M.et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int. J. Cancer. 105:2003;7-13.
22. Gilles C., Polette M., Seiki M., Birembaut P., Thompson E.W. Implication of collagen type I induced membrane type-1 matrix metalloproteinase expression in matrix metalloproteinase-2 activation in the metastastic progression of breast carcinoma. Lab. Invest. 76:1997;651-660.
23. Azzam H.S., Thompson E.W. Collagen-induced activation of the Mr 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res. 52:1992;4540-4544.
24. Coussens L.M., Raymond W.W., Bergers G.et al. Inflammarory mast cells up-regulate angiogenesis during squamous cell carcinogenesis. Genes Dev. 13:1999;1382-1397.
25. Biswas C., Zhang Y., DeCastro R., Gui H.et al. The human tumor cell derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 55:1995;434-439.
26. Caudroy S., Polette M., Tournier J.M.et al. Expression of the extracellular matrix metalloproteinase inducer EMMPRIN in bronchopulmonary and breast lesions. J. Histochem. Cytochem. 47:1999;665-670.
27. Muraoka K., Nabeshima K., Murayama T.et al. Enhanced expression of tumor-cell derived collagenase-stimulatory factor in urothelium carcinomas: its useful as a tumor marker for bladder cancers. Int. J. Cancer. 55:1993;19-26.
28. Van den Oord J.J., Paemen L., Opdenakker G.et al. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment lesions of the skin. Am. J. Pathol. 151:1997;665-670.
29. Polette M., Gilles C., Marchand V.et al. Tumor collagenase stimulatory factor (TCSF) expression and localisation in human lung and breast cancers. J. Histochem. Cytochem. 45:1996;703-707.
30. Zucker S., Hymowitz M., Rollo E.E.et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol. 158:2001;1921-1928.
31. Sun J., Hemler M.E. Regulation of MMP-1 and MMP-2 production through CD147/Extracellular matrix metalloproteinase inducer interactions. Cancer Res. 61:2001;2276-2281.
32. Caudroy S., Polette M., Nawrocki-Raby B.et al. EMMPRIN-mediated regulation in tumor and endothelial cells. Clin. Exp. Metastasis. 19:2002;697-702.
33. Ronnov-Jessen L., Petersen O.W. Induction of alpha smooth muscle actin by transforming growth factor type-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 68:1993;696-707.
34. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease cleavage of laminin-5. Science. 277:1997;225-228.
35. Gilles C., Polette M., Coraux C.et al. Contribution of MT1-MMP and a human laminin-5 γ2 chain degradation to mammary epithelial cell migration. J. Cell Sci. 114:2001;2967-2976.
36. Koshikawa N., Giannelli G., Cirulli V., Miyazaki K., Quaranta V. Role of cell surface metalloprotease 1 MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148:2000;615-624.
37. Petitclerc E., Boutaud A., Prestayko A.et al. New functions for noncollagenous domains of human collagen IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275:2000;8051-8061.
38. Catusse C., Polette M., Coraux C., Burlet H., Birembaut P. Modified membrane composition during bronchopulmonary tumor progression. J. Histochem. Cytochem. 48:2000;663-669.
39. Maeshima Y., Colorado P.C., Kalluri R. Two RGD-independent αvβ3 integrin binding sites in tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275:2000;23745-73750.
40. Martinella-Catusse C., Polette M., Noël A.et al. Down regulation of MT1-MMP by the alpha-3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab. Invest. 81:2001;167-175.
41. Monboisse J.C., Garnotel R., Bellon G.et al. The α3 chain of type IV collagen prevents activation of human polymorphonclear leucocytes. J. Biol. Chem. 269:1994;25475-25482.
42. Brassart B., Randoux A., Hornebeck W., Emonard H. Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinase-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosaroma cell line. Clin. Exp. Metastasis. 16:1998;489-500.
43. Jung S., Rutka J.T., Hinek A. Tropoelastin and elastin degradation products promote proliferation of human astrocytoma cell lines. J. Neuropathol. Exp. Neurol. 57:1998;439-448.
44. Marneros A.G., Olsen B.R. The role of collagen derived proteolytic fragments in angiogenesis. Matrix Biol. 20:2001;337-345.
45. Cornelius L.A., Nehring L.C., Harding E.et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161:1998;6845-6852.
46. Dong Z.Y., Kumar R., Yang X.I., Fidler I.J. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 88:1997;801-810.
47. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 153:1998;333-339.
48. Behrens J., von Kries J., Kuhk M.et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature. 382:1996;638-642.
49. Crawford H.C., Fingleton B.M., Rudolph-Owen L.A.et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in interstinal tumours. Oncogene. 18:1999;2883-2891.
50. Henderson B.R., Fagotto F. The ins and outs of APC and β-catenin nuclear transport. EMBO Rep. 3:2002;834-839.
51. Resnik E. β-catenin-one player, two games. Nature Genet. 16:1997;9-11.
52. Gilles C., Polette M., Mestdagt M.et al. Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Res. 63:2003;2658-2664.
53. Miyaki M., Tanaka K., Kikuchi-Yanoshita R.et al. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells. Oncogene. 11:1995;2547-2552.
54. Llorens A., Rodrigo I., Lopez-Barcons L.et al. Down-regulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Lab. Invest. 78:1998;1131-1142.
55. Luo J., Lubaroff D.M., Hendrix M.J.C. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res. 59:1999;3552-3556.
56. Nawrocki-Raby B., Gilles C., Polette M.et al. E-Cadherin mediates MMP downregulation in highly invasive bronchial tumor cells. Am. J. Pathol. 163:2003;653-661.
57. Noë V., Fingleton B., Jacobs K.et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114:2000;111-118.
58. Nawrocki-Raby B., Gilles C., Polette M.et al. Up-regulation of MMPs by soluble E-cadherin in human lung tumor cells. Int. J Cancer. 105:2003;790-795.
59. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194:2003;1-11.
60. Yu Q., Stamenkovic I. localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD-44 mediated tumor invasion. Gene Dev. 13:1999;35-48.
61. Dumin J.A., Dickeson S.K., Striker T.P.et al. Pro-collagenase 1 (matrix metalloproteinase-1) binds to the α2β1 integrin upon release from keratinocytes migrating on type I collagen. J. Biol. Chem. 276:2001;29368-29374.
62. Brooks P.C., Strömblad S., Sanders L.C.et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 85:1996;683-693.
63. Whitelock J.M., Murdoc A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase. J. Biol. Chem. 271:1996;10079-10086.
64. Fowlkes J.L., Thrailkill K.M., Serra D.M., Suzuki K., Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog. Growth factor Res. 6:1995;255-263.
65. Powell U.C., Fingleton B., Wilson C.L., Boothby M., Matrisian L.M. The metalloproteinase matrilysin proteolytically generates active soluble fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9:1999;1441-1447.
66. Bertaux B., Hornebeck W., Eisen A.Z., Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Invest. Dermatol. 97:1991;679-685.
67. Li G.Y., Fridman R., Kim H.R.C. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 59:1999;6267-6275.
68. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107:1994;2373-2379.
69. Gilles C., Thompson E.W. The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J. 2:1996;83-86.
70. Gilles C., Polette M., Zahm J.M.et al. Vimentin contributes to human epithelial cell migration. J. Cell Sci. 112:1999;4615-4625.
71. Hendrix M.J.C., Seftor E.A., Seftor R.E., Trevor K.T. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol. 150:1997;483-495.
72. Ahmad A., Hanby A., Dublin E.et al. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am. J. Pathol. 152:1998;721-728.
73. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115:2002;3719-3727.
74. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2002;2387-2392.